Zhang Yang, Rajput Ashwani, Jin Ning, Wang Jing
Department of Cancer Biology and Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Johns Hopkins Sidney Kimmel Cancer Center, National Capital Region, Sibley Memorial Hospital, 5255 Loughboro Road NW, Washington, DC 20016, USA.
Cancers (Basel). 2020 Dec 20;12(12):3850. doi: 10.3390/cancers12123850.
CRC is the third most diagnosed cancer in the US with the second-highest mortality rate. A multi-modality approach with surgery/chemotherapy is used in patients with early stages of colon cancer. Radiation therapy is added to the armamentarium in patients with locally advanced rectal cancer. While some patients with metastatic CRC are cured, the majority remain incurable and receive palliative chemotherapy as the standard of care. Recently, immune checkpoint blockade has emerged as a promising treatment for many solid tumors, including CRC with microsatellite instability. However, it has not been effective for microsatellite stable CRC. Here, main mechanisms of immunosuppression in CRC will be discussed, aiming to provide some insights for restoring immunosurveillance to improve treatment efficacy in CRC.
结直肠癌是美国第三大最常被诊断出的癌症,死亡率位居第二。早期结肠癌患者采用手术/化疗的多模式治疗方法。局部晚期直肠癌患者的治疗手段中会加入放射治疗。虽然一些转移性结直肠癌患者可被治愈,但大多数患者仍无法治愈,接受姑息化疗作为标准治疗方案。最近,免疫检查点阻断已成为许多实体瘤(包括微卫星不稳定的结直肠癌)的一种有前景的治疗方法。然而,它对微卫星稳定的结直肠癌无效。在此,将讨论结直肠癌中免疫抑制的主要机制,旨在为恢复免疫监视以提高结直肠癌治疗效果提供一些见解。